Male contraceptive formulation comprising norethisterone

US7025979B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Eberhard Nieschlag · Munster, DE
• Axel Kamischke · Munster, DE
• Michael Oettel · Jena, DE
• Alexander Ruebig · Berlin, DE
• Ekkerhard Schillinger · Berlin, DE
• Ursula Habenicht · Berlin, DE

Key dates

• Filing date: Jan 19, 2001
• Grant date: Apr 11, 2006
• Expiry date: May 6, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/569
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A formulation for male contraception comprising a progestin possessing both estrogenic and androgenic properties is remarkably effective for spermatogenesis suppression in males. The progestin Norethisterone (NET), particularly its derivatives Norethisterone acetate and Norethisterone enanthate in sufficient doses induce oligozoospermia or azoospermia in males. Formulations further comprising an androgen, such as a testosterone derivative such as a testosterone ester, particularly testosterone undecanoate, are especially effective male contraceptive formulations.